XTalks

FEBRUARY 21, 2024

Tirzepatide’s mechanism of action involves activating two naturally produced hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Clinical Trials for MASH Treatment The tirzepatide trial involved approximately 190 adults with MASH at different stages.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

XTalks

FEBRUARY 6, 2023

Erythropoietin is a hormone that is produced by the kidneys and signals the body to make red blood cells. Clinical Trial Outcomes The FDA approval of Jesduvroq is based on results from the Phase III ASCEND-D trial , which were published in the New England Journal of Medicine. How Does Jesduvroq ( daprodustat) Work?

FDA Approval 97

FDA Approval Clinical Trials Clinical Trials Trials 97

XTalks

JUNE 16, 2023

Notably, the EMPA-KIDNEY Phase III clinical trial results published in The New England Journal of Medicine revealed that Jardiance (empagliflozin), an SGLT2 inhibitor, significantly reduced the risk of kidney disease progression or death from cardiovascular causes compared to placebo in patients with pre-existing CKD.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Hormones 96

The Pharma Data

MARCH 23, 2023

The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.

Hormones 40

Hormones Trials Branding Development 40

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. The results still require further validation, including experimental and clinical evaluation. The list also included melatonin.

Research 98

Research Hormones Protein Regulation 98

XTalks

NOVEMBER 19, 2021

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

XTalks

FEBRUARY 3, 2023

Aditya Bardia, MD, MPH, director of Breast Cancer Research at Mass General Cancer Center, associate professor at the Medicine Department at Harvard Medical School and principal investigator for the EMERALD trial, in the same press release statement. Mutations in the ESR1 , however, have contributed to the rise of endocrine resistance.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

XTalks

DECEMBER 22, 2021

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

Life Science 98

Life Science RNA Vaccination Vaccine 98

The Pharma Data

APRIL 11, 2023

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program.

Research 40

Research Clinical Trials Clinical Trials Trials 40

XTalks

NOVEMBER 10, 2021

In the ASCEND trials, Daprodustat was comparable to Amgen’s Aranesp (darbepoetin alfa), an erythropoiesis-stimulating agent (ESA), with respect to heart safety. Darbepoetin alfa is a synthetic version of the hormone erythropoietin, which is made in the kidneys and stimulates the production of red blood cells (RBC), or erythrocytes.

Trials 97

Trials Hormones Drugs FDA Approval 97

XTalks

JUNE 27, 2022

Tafinlar and Mekinist Combination Clinical Trial Results. The safety and efficacy of the Tafinlar and Mekinist combination therapy was evaluated in three clinical trials. The safety profile of Tafinlar + Mekinist in these trials was consistent with data from its previous clinical trials.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Regulation 52

XTalks

MAY 10, 2023

The exact cause of lupus is not entirely understood, but it is thought to be from a combination of genetic, environmental and hormonal factors. Investigational Drugs in Phase III Clinical Trials for Lupus There are a couple of investigational drugs that are new molecular entities (NME) in Phase III trials for lupus.

Drugs 52

Drugs Clinical Trials Clinical Trials Antibody 52

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

The Pharma Data

FEBRUARY 21, 2022

The company is advancing around 50 projects in ongoing clinical trials across a range of potential therapeutic modalities and indications, with a focus on oncology, cardiovascular and women’s health. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Radiology 52

Radiology Cardiology Development Production 52

Drug Discovery World

APRIL 23, 2024

Concussive injuries have been overlooked and as a consequence, clinical trials for novel therapeutic approaches are just starting to appear. The majority of these programmes are in pre-clinical or Phase I studies. Neuronasal is studying N-acetyl cysteine, a known antioxidant which has shown promise in early trials of mild TBI.

Drugs 59

Drugs Development Life Science Hormones 59

XTalks

JULY 2, 2021

Currently, there is no scientific evidence to suggest that the vaccines induce any hormonal changes that would lead to irregular periods. This had led some to wonder whether period changes may be a potential side effect of the vaccines. Most physicians say there is nothing to worry about and that the changes are temporary.

Vaccination 105

Vaccination Vaccine Protein Immune Response 105

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Diamyd Medical is a clinical-stage biopharmaceutical company that develops therapies for type 1 diabetes.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. The efficacy and safety of Rybelsus in reducing blood sugar in patients with type 2 diabetes were investigated in various clinical trials.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

FEBRUARY 19, 2021

Evofem Biosciences announced the launch of their new national campaign called, “Get Phexxi,” designed to raise awareness about the company’s non-hormonal birth control method. In May 2020, the US Food and Drug Administration (FDA) approved Phexxi , a non-hormonal contraceptive for women.

Hormones 88

Hormones Production FDA Approval Marketing 88

XTalks

MAY 17, 2023

While the exact physiology of vasomotor symptoms is not fully understood, it is believed that the significant fluctuations in reproductive hormones play a role in triggering these symptoms. Hormone replacement therapy is thought to be one of the most effective treatments for vasomotor symptoms. How Does Veozah Work?

Hormones 95

Hormones FDA Approval Drugs Clinical Trials 95

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. The company’s menopause drug NT-814 is heading for phase 3 development in 2021 following a mid-stage trial readout.

Marketing 94

Marketing Gene Silencing Gene Drugs 94

XTalks

NOVEMBER 9, 2022

GLP-1 receptor agonists, or incretin (metabolic hormones) mimetics, are analogs of the GLP-1 peptide hormone that binds to the GLP-1 receptor to regulate blood sugar levels by boosting insulin secretion. GIP is a metabolic hormone that promotes insulin secretion and also weakly inhibits gastric acid secretion to suppress appetite.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The benefits of Verzenio are supported by promising clinical data. Internationally, revenue reached $355.7

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

MAY 27, 2022

This result came from the promising Phase III EMERALD global clinical trial ( NCT03778931 ). Recent studies in mouse models implanted with human tumor cells (xenografts) have shown that elacestrant exhibits significant anti-tumor activity , even in ESR1 mutated models resistant to hormone therapy. This oral drug binds to ER? —

Clinical Trials 98

Clinical Trials Clinical Trials Trials Gene 98

XTalks

MARCH 8, 2021

GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise. Semaglutide acts by inhibiting glucagon, which is a hormone that increases blood sugar. It combines the action of both glucose-lowering metabolic hormones into a single molecule.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

XTalks

MARCH 1, 2021

And while conventional dry eye can have a number of causes — including blepharitis, hormone-related changes in post-menopausal women and contact lens use — mask-associated dry eye is largely cropping up in people who wear face masks for extended periods during the day.

Sales 119

Sales Drugs Life Science Containment 119

XTalks

FEBRUARY 7, 2023

Current treatments for HR+ breast cancer patients include hormonal therapies, chemotherapies for those that do not respond to hormonal therapy alone and targeted therapies, either stand-alone or in combination with hormonal therapies. What does this Approval Mean for Breast Cancer Patients?

HR 52

HR Hormones FDA Approval Antibody 52

Drug Discovery World

MAY 9, 2024

RA: Tell us how OXE103 works? MW: OXE103 (ghrelin) is a 28 amino acid neuro-peptide hormone that crosses the blood brain barrier and is responsible for maintaining brain energy homeostasis and neuroprotection related to neuronal cell preservation, axonal connectivity and decreased inflammation. Rest Is not Enough!

Development 72

Development Hormones Drugs Trials 72

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The benefits of Verzenio are supported by promising clinical data. Internationally, revenue reached $355.7

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

MARCH 7, 2024

Optimizing Sleep During Perimenopause and Beyond Sleep plays a crucial role in overall health, particularly for midlife women transitioning into menopause, a phase marked by perimenopause where hormonal changes can severely disrupt sleep due to symptoms like nocturnal hot flashes.

Hormones 115

Hormones Genetics Genome Genomics 115

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. percent and 22.5 percent, respectively, compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion ($3.65

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.

HR 98

HR FDA Approval Gene Trials 98

XTalks

AUGUST 10, 2022

Approximately 80 to 85 percent of these cases were previously considered to be the HER2-negative subtype (which includes hormone receptor positive and triple negative breast cancer), which means the tumors do not make higher than normal amounts of the HER2 protein.

FDA Approval 98

FDA Approval HR Hormones Antibody 98

pharmaphorum

MARCH 5, 2021

For International Women’s Day, Medidata’s global compliance and strategy lead Fiona Maini discusses the importance of increasing female participation in clinical trials and how technology may solve some of the barriers. Levelling the field through technology.

Clinical Trials 113

Clinical Trials Clinical Trials Trials Vaccination 113

XTalks

NOVEMBER 2, 2020

This includes compromising the functioning of the adrenal glands, which can potentially lead to adrenal insufficiency, resulting in inadequate production of steroid hormones. While steroids are a common base drug that Fasenra is usually added on top of, frequent or chronic OCS use can lead to serious adverse effects.

Trials 94

Trials FDA Approval Hormones Drugs 94

The Pharma Data

MARCH 11, 2021

Speaking at the virtual Capital Markets Day on Wednesday, CEO Werner Baumann emphasized Bayer’s long-term growth perspectives: “Bayer is a leading life science company, uniquely positioned at the intersection of health and nutrition – with attractive prospects for growth, earnings and cash flow.”

Sales 52

Sales Gene Therapy Marketing Gene 52